E-mail: susanne.schnittger@mll.com
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker
- Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1, CEBPA, RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome
- Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation
- AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset?
- BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia
- Complexity of CEBPA Mutated Acute Myeloid Leukemia
- Cytogenetic and Molecular Genetic Shifts in 27 Genes Investigated By NGS Depict Specific Routes from MDS to s-AML in 38 Patients with Paired Samples
- DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML
- Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms?
- First Achievements of MPN&MPNr-EuroNet (COST Action BM0902), a New European Network Dedicated to the Diagnosis of Myeloproliferative Neoplasms and Hereditary Erythrocytosis and Thrombocytosis
- Genetic Patterns of Relapsed AML Differ Significantly from First Manifestation and Are Dependent on Cytogenetic Risk Groups at Diagnosis: Results in 175 Patients with Paired Samples
- In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML
- Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study
- INTERNATIONAL CONTROL ROUND FOR DEEP SEQUENCING ANALYSIS OF BCR-ABL KINASE DOMAIN MUTATIONS IN 11 LABORATORIES FROM 7 EUROPEAN COUNTRIES
- International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MR
- Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/CBFB-MYH11
- Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
- Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity?
- Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients
- Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV
- Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.
- Specific Patterns of Molecular Mutations Determine the Morphologic Differentiation Stages in Acute Myeloid Leukemia (AML)
